Towards developing criteria for scleroderma renal crisis: A scoping review.

[1]  T. Medsger,et al.  Hypertension and Renal Failure (Scleroderma Renal Crisis) in Progressive Systemic Sclerosis: REVIEW OF A 25‐YEAR EXPERIENCE WITH 68 CASES , 1983, Medicine.

[2]  T. Medsger,et al.  Factors predicting development of renal involvement in progressive systemic sclerosis. , 1984, The American journal of medicine.

[3]  H. Kondo,et al.  Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis. , 1994, The Journal of rheumatology.

[4]  C. Ferri,et al.  Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? , 1996, The Journal of rheumatology.

[5]  G. Valentini,et al.  Scleroderma Renal Crisis Analysis of Prevalence and Outcome in a Large Italian Series , 1997, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[6]  T. Medsger,et al.  Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. , 1998, Arthritis and rheumatism.

[7]  P. Clements,et al.  Thrombotic thrombocytopenia purpura in a patient with systemic sclerosis. , 2001, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[8]  Richard W. Martin,et al.  Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. , 2002, Arthritis and rheumatism.

[9]  M. Mayes,et al.  Assessment of kidney involvement. , 2003, Clinical and experimental rheumatology.

[10]  R. Moots,et al.  An unusual cause of acute renal failure in systemic sclerosis , 2003, Annals of the rheumatic diseases.

[11]  J. Walker,et al.  Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment , 2003, Internal medicine journal.

[12]  J. Block,et al.  Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis. , 2005, Seminars in arthritis and rheumatism.

[13]  T. Medsger,et al.  Kidney disease other than renal crisis in patients with diffuse scleroderma. , 2005, The Journal of rheumatology.

[14]  H. Arksey,et al.  Scoping studies: towards a methodological framework , 2005 .

[15]  C. Denton,et al.  Scleroderma renal crisis: patient characteristics and long-term outcomes. , 2007, QJM : monthly journal of the Association of Physicians.

[16]  N. Washida,et al.  ACE inhibitor-induced acute renal failure in a patient with progressive systemic sclerosis: ischemic nephropathy mimicking PSS renal crisis. , 2007, Internal medicine.

[17]  L. Mouthon,et al.  Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients , 2007, Annals of the rheumatic diseases.

[18]  M. Mayes,et al.  Association of RNA Polymerase III Antibodies with Scleroderma Renal Crisis , 2010, The Journal of Rheumatology.

[19]  Kazuhiko Yamamoto,et al.  Thrombotic thrombocytopenic purpura with severe hypertension in a patient with systemic sclerosis sine scleroderma and polymyositis. , 2011, Internal medicine.

[20]  U. Arad,et al.  Anti-neutrophil antibody associated vasculitis in systemic sclerosis. , 2011, Seminars in arthritis and rheumatism.

[21]  M. Mayes,et al.  HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis. , 2011, Arthritis and rheumatism.

[22]  P. Nash,et al.  Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort , 2011, Arthritis research & therapy.

[23]  R. Steele,et al.  Longitudinal Study of Renal Function in Systemic Sclerosis , 2012, The Journal of Rheumatology.

[24]  R. Hesselstrand,et al.  Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor , 2012, Scandinavian journal of rheumatology.

[25]  C. Mok,et al.  Pauci-immune crescentic glomerulonephritis in limited cutaneous systemic sclerosis , 2012, Clinical Rheumatology.

[26]  Y. Tada,et al.  Increased serum soluble CD147 levels in patients with systemic sclerosis: association with scleroderma renal crisis , 2012, Clinical Rheumatology.

[27]  L. Mouthon,et al.  Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. , 2012, Rheumatology.

[28]  Y. Tada,et al.  An inverse correlation of serum angiogenin levels with estimated glomerular filtration rate in systemic sclerosis patients with renal dysfunction. , 2013, European journal of dermatology : EJD.

[29]  R. Scorza,et al.  Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series. , 2013, Clinical and experimental rheumatology.

[30]  M. Mayes,et al.  An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative , 2013 .

[31]  M. Court-Payen,et al.  Imaging in juvenile idiopathic arthritis with a focus on ultrasonography. , 2013, Clinical and experimental rheumatology.

[32]  S. Badwal,et al.  Unusual case of pulmonary renal syndrome with autopsy findings. , 2013, Indian journal of pathology & microbiology.

[33]  A. Wells,et al.  Prediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis , 2014, Arthritis & rheumatology.

[34]  A. Rajić,et al.  A scoping review of scoping reviews: advancing the approach and enhancing the consistency , 2014, Research synthesis methods.

[35]  M. Hudson,et al.  Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. , 2014, Seminars in arthritis and rheumatism.

[36]  M. Fujimoto,et al.  Reply: To PMID 25512203. , 2015, Arthritis & rheumatology.

[37]  L. Hummers,et al.  Oxalate nephropathy in systemic sclerosis: Case series and review of the literature. , 2015, Seminars in arthritis and rheumatism.

[38]  Y. Tada,et al.  A possible contribution of lipocalin‐2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis , 2015, The British journal of dermatology.

[39]  C. Vasconcelos,et al.  Quality of life in systemic sclerosis. , 2015, Autoimmunity reviews.

[40]  M. Flessner,et al.  An unusual cause of acute kidney injury due to oxalate nephropathy in systemic scleroderma. , 2014, Clinical nephrology.

[41]  M. Fujimoto,et al.  Clinical and Immunologic Predictors of Scleroderma Renal Crisis in Japanese Systemic Sclerosis Patients With Anti–RNA Polymerase III Autoantibodies , 2015, Arthritis & rheumatology.

[42]  P. Cacoub,et al.  Systemic sclerosis: An update in 2016. , 2016, Autoimmunity reviews.

[43]  P. Mandich,et al.  Genetic factors and systemic sclerosis. , 2016, Autoimmunity reviews.

[44]  Dean Giustini,et al.  De-duplication of database search results for systematic reviews in EndNote. , 2016, Journal of the Medical Library Association : JMLA.

[45]  T. Gambichler,et al.  RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis , 2016, International journal of dermatology.

[46]  L. Czirják,et al.  Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study , 2013, Annals of the rheumatic diseases.